+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Boehringer Ingelheim GmbH - Product Pipeline Review - 2015

1 of 4
Boehringer Ingelheim GmbH - Product Pipeline Review - 2015

Summary

The report ‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2015’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boehringer Ingelheim GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Boehringer Ingelheim GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Boehringer Ingelheim GmbH’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Boehringer Ingelheim GmbH’s pipeline products

Reasons to buy

- Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Boehringer Ingelheim GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Boehringer Ingelheim GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Boehringer Ingelheim GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Boehringer Ingelheim GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Boehringer Ingelheim GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Loading
LOADING...

3 of 4
List of Tables
List of Figures
Boehringer Ingelheim GmbH Snapshot
Boehringer Ingelheim GmbH Overview
Key Information
Key Facts
Boehringer Ingelheim GmbH - Research and Development Overview
Key Therapeutic Areas
Boehringer Ingelheim GmbH - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Boehringer Ingelheim GmbH - Pipeline Products Glance
Boehringer Ingelheim GmbH - Late Stage Pipeline Products
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products
Boehringer Ingelheim GmbH - Early Stage Pipeline Products
Boehringer Ingelheim GmbH - Drug Profiles
(empagliflozin + metformin hydrochloride)
(olodaterol + tiotropium bromide)
idarucizumab
tiotropium bromide
adalimumab biosimilar
afatinib dimaleate
bevacizumab biosimilar
empagliflozin
nintedanib
rituximab biosimilar
volasertib
BI-144807
BI-409306
BI-655066
FX-125L
VTP-34072
BI-836845
BI-836858
BI-1005273
BI-1015550
BI-1026706
BI-1060469
BI-113608
BI-1361849
BI-416970
BI-425809
BI-655064
BI-836826
BI-847325
BI-853520
BI-860585
PXS-4728A
Small Molecule for Cancer
BCA-909
BI-1147560
BI-186908
BI-207524 Follow-Up
BIBN-4096BS
CNX-012
CNX-012570
Monoclonal Antibodies for Autoimmune Disorders
Monoclonal Antibodies for Oncology and Immunology
Small Molecule 2 for Cancer
Small Molecule 3 for Cancer
Small Molecule for Respiratory Diseases
Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain
Small Molecule to Agonize Glucocorticoid Receptor for Inflammation
Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection
Small Molecules for Respiratory Disorders
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy
Synthetic Peptide for CardioMetabolic Disease
Synthetic Peptides to Agonize Glucagon and GLP-1 for Metabolic Disorders
Antibody for Cancer
BI-665915
Monoclonal Antibody for Undisclosed Indication
Small Molecule 2 to Agonize Glucocorticoid Receptor for Inflammation
Small Molecule for HIV
Small Molecule for HIV-1 Infection
Small Molecule to Agonize Glucocorticoid Receptor for Undisclosed Indication
Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders
Small Molecule to Inhibit Reverse Transcriptase for HIV-1
Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection
Small Molecules for Cancer
Small Molecules for Undisclosed Indication
Small Molecules to Inhibit K-Ras for Oncology
Small Molecules to Inhibit Kinases for Cancer
Boehringer Ingelheim GmbH - Pipeline Analysis
Boehringer Ingelheim GmbH - Pipeline Products by Target
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action
Boehringer Ingelheim GmbH - Recent Pipeline Updates
Boehringer Ingelheim GmbH - Dormant Projects
Boehringer Ingelheim GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Boehringer Ingelheim GmbH, Key Information
Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH - Pipeline by Indication, 2015
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2015
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
Boehringer Ingelheim GmbH - Pre-Registration, 2015
Boehringer Ingelheim GmbH - Phase III, 2015
Boehringer Ingelheim GmbH - Phase II, 2015
Boehringer Ingelheim GmbH - Phase I, 2015
Boehringer Ingelheim GmbH - Preclinical, 2015
Boehringer Ingelheim GmbH - Discovery, 2015
Boehringer Ingelheim GmbH - Pipeline by Target, 2015
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2015
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2015
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2015
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2015
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2015
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2015
Boehringer Ingelheim GmbH, Subsidiaries

List of Figures
Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2015
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2015
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2015
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Route of Administration, 2015
Boehringer Ingelheim GmbH - Pipeline by Top 10 Molecule Type, 2015
Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll